Vazyme

Nanjing Vazyme Biotechnology Co., Ltd. (stock code 688105), founded in 2012 and located in the Nanjing Economic and Technological Development Zone, is a biotechnology enterprise engaged in the research and development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials, as well as product development. Relying on its independently established key common technology platforms, it has successively entered business areas such as life sciences, in vitro diagnostics, and biomedicine. It is one of the few innovative enterprises in China with both independent and controllable upstream technology development capabilities and terminal product production capabilities, committed to manufacturing "biochips" and continuously injecting new vitality into the development of the biotechnology industry.

R&D innovation capabilities and talent reserve: Vazyme has always adhered to innovation and strived for breakthroughs, insisting on starting R&D from the source of technology. Leveraging its independent core technologies, it has built independent and controllable key common technology platforms, enabling rapid, efficient, and large-scale product development. Currently, it possesses over 600 genetic engineering recombinant enzymes and over 2,500 high-performance antigens and monoclonal antibodies as key raw materials, and has more than 2,000 terminal products, which can be widely applied in scientific research, high-throughput sequencing, in vitro diagnostics, medicine and vaccine development, and animal quarantine, among other fields.

Strong R&D strength is supported by a talent team. Vazyme has an R&D innovation team of nearly 700 people, composed of interdisciplinary researchers in fields such as molecular biology, enzymology, immunology, bioinformatics, organic chemistry, and materials science, with over 67% of R&D personnel holding master's degrees or above.

Mastering core raw material technologies and aggregating downstream industry advantages: Since its inception, Vazyme has adhered to an R&D-centric business philosophy, relying on its independent core technologies, continuously upgrading and iterating technological advancements, and exploring new business areas. Through years of dedicated pursuit, Vazyme has achieved technical accomplishments in the fields of biology, healthcare, and medicine. It has successfully launched multiple series of biological reagents, including high-throughput sequencing library preparation series, PCR series, qPCR series, molecular cloning series, reverse transcription series, and Bio-assay series, as well as 9 series of POCT diagnostic reagents covering cardiovascular and cerebrovascular diseases, inflammatory infections, prenatal and postnatal care, gastric function, respiratory system, nervous system, and others, along with new drug R&D reagents. It has formed a customer base covering research institutions, high-throughput sequencing service enterprises, molecular diagnostic reagent manufacturers, pharmaceutical companies, CRO companies, hospitals, and other medical institutions.

Upholding the mission and fulfilling responsibilities: While expanding and deepening product and technology chains, Vazyme always adheres to the mission of "fulfilling healthy life through technology," around the cycle of disease "discovery, diagnosis, prevention, and treatment," continuously developing new technologies, providing high-quality products and professional services, and creating value for customers.

Vazyme values its employees as the foundation, providing a broad development platform to attract outstanding talents from across the country and the world, promoting the overall development and enhancement of China's biomedical and medical technology industry. Vazyme actively participates in the construction of public health undertakings, using technology to support national biosecurity construction, and helping humanity overcome major infectious diseases, tumors, and autoimmune diseases!